KPC Pharmaceuticals,Inc

600422

CNE0000015P8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
20.17 ^CNY	-1.85%		-10.79%	-3.31%

04-19	KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-17	Kunyao Group Receives Clinical Trial Approval for FMF Drug	MT

KPC Pharmaceuticals, Inc. Announces Executive Changes

October 12, 2017

KPC Pharmaceuticals, Inc. announced that at its board meeting held on October 13, 2017, the board approved the resignation of Dong Shaoyu as vice president and also approved the proposal of appointing Wang Jun as Vice President.

Latest news about KPC Pharmaceuticals,Inc

KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Kunyao Group Receives Clinical Trial Approval for FMF Drug	04-16	MT
KPC Pharmaceuticals,Inc Proposes Cash Dividend	03-21	CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
KPC Pharmaceuticals’ Antimalarial Drug Passes WHO Prequalification	23-10-13	MT
KPC Pharmaceuticals' Attributable Profit Rises 3.1%; Shares Slip 4%	23-08-29	MT
KPC Pharmaceuticals,Inc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
KPC Pharmaceuticals' Q1 Net Profit Jumps; Shares Rise 7%	23-04-27	MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
KPC Pharma’s Shingles Drug Added to China’s Medical Insurance Catalog	23-01-20	MT
KPC Pharma to Hold Phase II Clinical Trial of Stroke Drug	23-01-20	MT
China Resources Pharmaceutical Completes Transfer of KPC Pharmaceutical Shares to Unit	23-01-02	MT
KPC Pharmaceuticals CFO Steps Down	23-01-02	MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. completed the acquisition of a 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited.	22-12-29	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
KPC Pharmaceuticals Unit Receives Marketing Authorization of Angong Niuhuang Pills; Shares Jump 7%	22-10-21	MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Chinese Shares Rebound; KPC Pharma Rallies 10% on CR Sanjiu’s $431 Million Stake Purchase	22-05-10	MT
CR Sanjiu Medical & Pharma to Buy 28% Stake in KPC Pharma For $430 Million	22-05-09	MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited for CNY 2.9 billion.	22-05-07	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-15	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-18	CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-21	CI
Kpc Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-13	CI

Chart KPC Pharmaceuticals,Inc

Duration

Period

More charts

Company Profile

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for KPC Pharmaceuticals,Inc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.17 CNY

Average target price

25.01 CNY

Spread / Average Target

+24.00%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KPC PHARMACEUTICALS,INC	-3.31%	2.11B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals